ADMA Biologics Stock Plunges As Legal Probes Escalate

ADMA Biologics Inc stocks have been trading down by -3.54 percent amid heightened concern over its latest clinical trial setback.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading ADMA

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

What Traders Need To Know

Short-seller Culper Research alleged that ADMA Biologics boosted its reported 2025 revenue growth from an underlying -3% to +20% by channel stuffing its ASCENIV product with a distributor.
Following the Culper Research report and a Cantor Fitzgerald downgrade criticizing ADMA’s response, the stock fell over 28% in two days.
Shares dropped about 29% after the allegations, prompting Bleichmar Fonti & Auld LLP to launch a securities-fraud investigation and solicit investors for a potential class action.
Rosen Law Firm is preparing a securities class action on behalf of ADMA shareholders after the channel-stuffing report, tied to a 16.6% stock drop on 2026/03/24.
Pomerantz LLP is also investigating ADMA Biologics for potential securities fraud after the same allegations, adding further legal and headline risk around the name.

Weekly Update May 04 – May 08, 2026: On Friday, May 08, 2026 ADMA Biologics Inc stock [NASDAQ: ADMA] is trending down by -3.54%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – negative

ADMA Biologics now screens as a high‑margin, cash‑generative plasma therapeutics player with unusually strong fundamentals for a small‑cap biotech. Revenue of ~$510M with 3‑ and 5‑year CAGRs near 50–65% and gross margin of 57% support an EBITDA margin of ~39% and EBIT margin of 37%. ROIC above 30% and ROE ~36% are exceptional versus biotech peers, while leverage is modest (debt/equity 0.17, interest coverage ~28x) and liquidity robust (current ratio 6.7, Q1’26 FCF ~$56M).

Technically, the stock just experienced a violent repricing: a collapse from the low‑$10s to sub‑$8, followed by stabilization in the low‑$8s. The weekly tape shows a gap down (10.35 to 7.59) with a weak bounce to 8.43 and subsequent close at 8.17, consistent with heavy volume distribution and a new bearish trend. For trading, $8.50 is the key pivot: below it, sellers remain in control; only a sustained reclaim above $9.25 would confirm a tradable reversal.

More Breaking News

Near term, the Culper report and multiple class‑action investigations around alleged channel stuffing and related‑party distribution practices are the dominant drivers, and they materially elevate governance and restatement risk. Until ADMA provides transparent, verifiable rebuttals and its auditor signs off on inventory and distribution accounting, the stock will trade at a discount to healthcare and biotech benchmarks despite superior margins. Base case: range‑bound, volatile trading with resistance at $9.50, support near $7.25; risk‑adjusted stance is underweight with a cautious 12‑month fair value around $9.

Quick Financial Overview

ADMA Biologics Inc shows strong recent financial performance on paper. Quarterly revenue of about $114.5M feeds into trailing revenue near $510.2M, with three-year growth above 49% and five-year growth above 64%. Profitability metrics are unusually high for a small-cap biotech, with gross margin at 57.4%, EBITDA margin at 38.9%, and total profit margin around 28.8%. Return on equity above 14% and return on capital above 9% point to efficient use of capital, while a P/E near 16.8 and price-to-sales around 4.7 place ADMA in a premium but not extreme valuation band for a high-growth healthcare name.

Balance sheet strength is another key point for traders. Current ratio of 6.7 and quick ratio of 3.5 indicate ample liquidity, and total debt-to-equity of 0.17 with interest coverage around 27.9 reduce solvency risk. Cash and equivalents near $138.2M and free cash flow of roughly $55.7M in the latest quarter give ADMA Biologics Inc room to navigate legal costs or temporary business disruption. Receivables and inventory are large, with inventory around $222.1M, which now matters more given the channel-stuffing claims tied to ASCENIV.

On the tape, the damage from the short report is clear. Weekly data show ADMA dropping from above $10.30 to a low near $7.58 before stabilizing around $8.17, which is a fast reset of roughly 20% from recent highs and over 28% from pre-report levels. Intraday action around $8.70–$8.90 early in the session faded into a tight afternoon range between roughly $8.09 and $8.20, pointing to consolidation after the initial flush. For short-term traders, that $7.60 zone stands out as near-term support, while the $8.80–$9.00 area is the first real upside band where trapped longs may look to sell.

Conclusion

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!